NDA 017588 · Azurity
Gleostine
Lomustine · Oral · Alkylating Drug
NovelLast checked: Nov 20, 2026Latest source record: Jun 4, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
Aug 4, 1976
Approved uses
1
Original approval plus efficacy supplements
Registered trials
135
49 Phase 3, 15 recruiting
FAERS reports
2,597
1,796 serious, 587 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DELAYED MYELOSUPPRESSION and RISK OF OVERDOSAGE DELAYED MYELOSUPPRESSION Lomustine causes myelosuppression including fatal myelosuppression. Myelosuppression is delayed, dose-related, and cumulative; occurring 4 to 6 weeks after drug administration and persisting for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from lomustine is manifested by greater severity and longer duration of cytopenias. Monitor blood counts for at least 6 weeks after each dose. Do not give lomustine more frequently than every 6 weeks [see Warnings and Precautions ( 5.1 ), Dosage and Administration ( 2.2 , 2.3 )] . RISK OF OVERDOSAGE PRESCRIBE, DISPENSE, AND ADMINISTER ONLY ENOUGH CAPSULES FOR ONE DOSE. Fatal toxicity occurs with overdosage of lomustine . Both physician and pharmacist should emphasize to the patient that only one dose of lomustine is...
What it is approved for
From the label in effect Feb 12, 2026.
Lomustine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. ( 1 ) 1.1 Brain Tumors Lomustine is indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical and/or radiotherapeutic procedures. 1.2 Hodgkin's Lymphoma Lomustine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy.
Mechanism: Lomustine alkylates DNA and RNA. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 4, 1976 Original approval · Type 1 - New Molecular Entity
4 products under this application
- GLEOSTINE · LOMUSTINE 40MG · CAPSULE, ORAL · Prescription · TE AB
- GLEOSTINE · LOMUSTINE 100MG · CAPSULE, ORAL · Prescription · TE AB
- GLEOSTINE · LOMUSTINE 10MG · CAPSULE, ORAL · Prescription · TE AB
- GLEOSTINE · LOMUSTINE 5MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Lomustine" as an intervention, any sponsor and status, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple MyelomaPivotal-lookingStatus unknown
Riverside Haematology GroupAcademic, hospital or other
NCT00003603 · 660 participants (planned) · Start Mar 1998
Drug: cyclophosphamide; dexamethasone and 4 more · For: Multiple Myeloma and Plasma Cell Neoplasm
Sites: London, United Kingdom
- Bevacizumab and Lomustine for Recurrent GBMPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT01290939 · 592 participants · Start Oct 2011 · Primary completion Oct 2015
Drug: bevacizumab; lomustine · For: Glioblastoma Multiforme; Cognition Disorders; Disability Evaluation
Sites: Rotterdam, Netherlands; The Hague, Netherlands
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT00303810 · 567 participants · Start Jan 2001 · Primary completion Dec 2013
Drug: carboplatin; cisplatin and 7 more · For: Brain and Central Nervous System Tumors
Sites: Hamburg, Germany
- Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBMPivotal-lookingActive, not recruiting
CarTheraIndustry
NCT05902169 · 560 participants (planned) · Start Jan 29, 2024 · Primary completion Jan 28, 2028
Drug: Carboplatin; Lomustine and 1 more · For: Glioblastoma; Recurrent Glioblastoma; GBM
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 56 sites in all
- Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk MedulloblastomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00085735 · 549 participants · Start Apr 30, 2004 · Primary completion Mar 31, 2016
Drug: Cisplatin; Cyclophosphamide and 2 more · For: Medulloblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 197 sites in all
- Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant GliomaPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00052455 · 500 participants (planned) · Start Oct 2002
Drug: lomustine; procarbazine hydrochloride and 2 more · For: Brain and Central Nervous System Tumors
Sites: London, United Kingdom
- Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years OldPivotal-lookingCompleted
University Hospital, BordeauxAcademic, hospital or other
NCT00590837 · 459 participants · Start Feb 2008 · Primary completion Dec 2012
Drug: Lomustine · For: Acute Myeloid Leukemia
Sites: Amiens, France; Angers, France; Annecy, France · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death273
- off label use254
- nausea232
- fatigue219
- thrombocytopenia187
- disease progression144
- neutropenia134
- drug ineffective126
- platelet count decreased114
- vomiting110
- seizure92
- headache87
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 11 |
| 2008 | 11 |
| 2009 | 21 |
| 2010 | 26 |
| 2011 | 16 |
| 2012 | 54 |
| 2013 | 30 |
| 2014 | 54 |
| 2015 | 73 |
| 2016 | 94 |
| 2017 | 247 |
| 2018 | 298 |
| 2019 | 291 |
| 2020 | 232 |
| 2021 | 238 |
| 2022 | 222 |
| 2023 | 219 |
| 2024 | 156 |
| 2025 | 152 |
| 2026 | 134 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gleostine (Lomustine)
2024 spending
$3.5M
Beneficiaries
831
2,969 claims
Per beneficiary
$4,183
$692.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,536,478 |
| 2021 | $24,112 |
| 2022 | $0 |
| 2023 | $2,702,189 |
| 2024 | $3,476,288 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, et al. · Pharmacol Res 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W, Gorlia T, Bendszus M, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Clinical Guidelines for Canine Transmissible Venereal Tumour Treatment: Systematic Review and Meta-Analysis.
Pimentel PAB, Giuliano A, Odatzoglou P, et al. · Vet Comp Oncol 2025 · Systematic Review, Meta-Analysis
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Buckner JC, Shaw EG, Pugh SL, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, et al. · Lancet 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ, Gajjar A, Vezina G, et al. · J Clin Oncol 2006 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.